Log In
Print
BCIQ
Print
Print this Print this
 

VB-111

  Manage Alerts
Collapse Summary General Information
Company VBL Therapeutics Ltd.
DescriptionDual anti-angiogenic and vascular disruptive agent (VDA) that uses VBL's Vascular Targeting System technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today